放疗结合吉非替尼治疗非小细胞肺癌患者的临床疗效

Clinical Efficacy of Radiotherapy Combined with Gefitinib in the Treatment of Patients with Non-small Cell Lung Cancer

目的探究放疗结合吉非替尼治疗非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)患者的疗效。方法回顾性选取2021年2月—2023年2月临沂市中心医院收治的94例NSCLC患者的临床资料,按不同治疗方法分为两组,每组47例。对照组应用放疗治疗,研究组应用放疗结合吉非替尼治疗。比较两组临床疗效、血清肿瘤标志物、T淋巴细胞水平。结果与对照组比较,研究组临床疗效更高,各项血清肿瘤标志物水平更低,T淋巴细胞水平变化幅度更小,差异有统计学意义(P均<0.05)。结论放疗结合吉非替尼应用于治疗患者当中具有较高的临床疗效,可改善其免疫功能。

Objective To explore the efficacy of radiotherapy combined with gefitinib in the treatment of patients with non-small cell lung cancer(NSCLC).Methods The clinical data of 94 patients with NSCLC admitted to Linyi Central Hospital from February 2021 to February 2023 were retrospectively selected and divided into two groups with 47 cases in each group by different treatment methods.The control group was treated with radiotherapy,and the study group was treated with radiotherapy combined with gefitinib.The clinical efficacy,serum tumor markers and T lymphocyte levels were compared between the two groups.Results Compared with the control group,the clinical efficacy of the study group was higher,the levels of serum tumor markers were lower,and the changes of T lymphocyte levels were smaller,the differences were statistically significant(all P<0.05).Conclusion The application of radiotherapy combined with gefitinib in the treatment of patients has a high clinical effect,can improve their immune function.